UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 333

Sortiert nach

4 - Monoclonal antibody to Her-2 in breast cancer

Target Validation in Drug Discovery, 2007, p.69-81

2007

Volltextzugriff (PDF)

Abstract 1619: ERK-targeted therapy suppresses tumorigenicity in ovarian clear cell carcinoma and is modulated by ERK-binding protein PEA-15

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.1619-1619

2010

Volltextzugriff (PDF)

Abstract 3927: Obesity induces changes in adipokines profile and activates Akt/mTOR signaling accelerating breast carcinogenesis and tumor growth

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.3927-3927

2014

Volltextzugriff (PDF)

Abstract 5469: Trastuzumab resistant HER2+ breast cancer cells retain sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.5469-5469

2014

Volltextzugriff (PDF)

Abstract 959: ERα1 represses breast cancer EMT by inhibiting EGFR-mediated downregulation of E-cadherin

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.959-959

2012

Volltextzugriff (PDF)

Abstract B231: Jab1/Csn5 a new player driving the resistance to Her2-targeted therapies for breast cancer

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.B231-B231

2013

Volltextzugriff (PDF)

Abstract C120: Genomic landscape in advanced metaplastic breast cancer and outcomes with mTOR targeted therapy

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.C120-C120

2013

Volltextzugriff (PDF)

Abstract LB-165: Personalized prognostic prediction models for breast cancer recurrence and survival incorporating multidimensional data

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.LB-165-LB-165

2017

Volltextzugriff (PDF)

Abstract LB-379: Combating trastuzumab resistance by targeting Src, a common node downstream of multiple resistance pathways

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.LB-379-LB-379

2011

Volltextzugriff (PDF)

Abstract P4-07-10: Gene expression profiling in immunophenotypic triple negative breast carcinomas harboring HER-2 amplification identifies tumors with distinct molecular signatures and increased ERBB2 gene expression

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P4-P4-07-10

2020

Volltextzugriff (PDF)

Abstract P5-19-23: A phase I clinical trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in human epidermal growth factor receptor-2 positive (HER2+) metastatic breast cancer

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.P5-P5-19-23

2015

Volltextzugriff (PDF)

Actividad física y factores de riesgo cardiovascular y metabólico en la población general

Medicina clínica, 2003, Vol.121 (15), p.565-569

2003

Volltextzugriff (PDF)

Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells

Molecular cancer therapeutics, 2008-07, Vol.7 (7), p.1846-1850

2008

Volltextzugriff (PDF)

Adaptación y validación de la ICU Mobility Scale en España

Enfermería intensiva, 2020-07, Vol.31 (3), p.131-146

2020

Volltextzugriff (PDF)

Adaptation and validation of the ICU Mobility Scale in Spain

Enfermería Intensiva (English ed.), 2020-07, Vol.31 (3), p.131-146

2020

Volltextzugriff (PDF)

Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy

Molecular cancer therapeutics, 2007-01, Vol.6 (1), p.227-235

2007

Volltextzugriff (PDF)

Adjuvant Chemotherapy and Biological Therapies for Early-Stage Breast Cancer

Early Breast Cancer, 2013, p.478-488

2013

Volltextzugriff (PDF)

ADJUVANT SYSTEMIC THERAPY FOR PRIMARY BREAST CANCER

The Surgical clinics of North America, 1999-10, Vol.79 (5), p.1075-1090

1999

Volltextzugriff (PDF)

Adjuvant Therapy with Trastuzumab for HER‐2/neu‐Positive Breast Cancer

The oncologist (Dayton, Ohio), 2006-09, Vol.11 (8), p.857-867

2006

Volltextzugriff (PDF)

Age differences in presentation, diagnosis pathway and management of colorectal cancer

Cancer epidemiology, 2014-08, Vol.38 (4), p.346-353

2014

Volltextzugriff (PDF)

Allogeneic bone marrow transplantation in a patient with hypereosinophilic syndrome

American journal of hematology, 1996-02, Vol.51 (2), p.164-165

1996

Volltextzugriff (PDF)

Altered Expression of Sialylated Glycoproteins in Breast Cancer Using Hydrazide Chemistry and Mass Spectrometry

Molecular & cellular proteomics, 2012-06, Vol.11 (6), p.M111.011403-M111.011403, Article M111.011403

2012

Volltextzugriff (PDF)

Ameli-01: Phase I, Open Label Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), Administered in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Blood, 2020-11, Vol.136 (Supplement 1), p.41-42

2020

Volltextzugriff (PDF)

Antibody-drug conjugates in triple negative breast cancer

Future oncology (London, England), 2018-10, Vol.14 (25), p.2651-2661

2018

Volltextzugriff (PDF)

Are Biosimilars the Future of Oncology and Haematology?

Drugs (New York, N.Y.), 2019-10, Vol.79 (15), p.1609-1624

2019

Volltextzugriff (PDF)

1 – 25 von 333

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(301)
Mit Volltextzugriff
(318)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

4 - Monoclonal antibody to Her-2 in breast cancer

Abstract 1619: ERK-targeted therapy suppresses tumorigenicity in ovarian clear cell carcinoma and is modulated by ERK-binding protein PEA-15

Abstract 3927: Obesity induces changes in adipokines profile and activates Akt/mTOR signaling accelerating breast carcinogenesis and tumor growth

Abstract 5469: Trastuzumab resistant HER2+ breast cancer cells retain sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition

Abstract 959: ERα1 represses breast cancer EMT by inhibiting EGFR-mediated downregulation of E-cadherin

Abstract B231: Jab1/Csn5 a new player driving the resistance to Her2-targeted therapies for breast cancer

Abstract C120: Genomic landscape in advanced metaplastic breast cancer and outcomes with mTOR targeted therapy

Abstract LB-165: Personalized prognostic prediction models for breast cancer recurrence and survival incorporating multidimensional data

Abstract LB-379: Combating trastuzumab resistance by targeting Src, a common node downstream of multiple resistance pathways

Abstract P4-07-10: Gene expression profiling in immunophenotypic triple negative breast carcinomas harboring HER-2 amplification identifies tumors with distinct molecular signatures and increased ERBB2 gene expression

Abstract P5-19-23: A phase I clinical trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in human epidermal growth factor receptor-2 positive (HER2+) metastatic breast cancer

Actividad física y factores de riesgo cardiovascular y metabólico en la población general

Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells

Adaptación y validación de la ICU Mobility Scale en España

Adaptation and validation of the ICU Mobility Scale in Spain

Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy

Adjuvant Chemotherapy and Biological Therapies for Early-Stage Breast Cancer

ADJUVANT SYSTEMIC THERAPY FOR PRIMARY BREAST CANCER

Adjuvant Therapy with Trastuzumab for HER‐2/neu‐Positive Breast Cancer

Age differences in presentation, diagnosis pathway and management of colorectal cancer

Allogeneic bone marrow transplantation in a patient with hypereosinophilic syndrome

Altered Expression of Sialylated Glycoproteins in Breast Cancer Using Hydrazide Chemistry and Mass Spectrometry

Antibody-drug conjugates in triple negative breast cancer

Are Biosimilars the Future of Oncology and Haematology?

Suchergebnisse filtern